Literature DB >> 7905873

Vascular relaxing mechanism of denopamine in isolated canine coronary, femoral, mesenteric, and renal arteries.

J Aikawa1, M Moroi, A Namiki, T Yamaguchi, K Machii, K Koike, I Takayanagi.   

Abstract

We investigated the mechanism of vascular relaxation produced by denopamine (deno), an oral positive inotropic agent that has selective beta 1-adrenergic action. Deno concentration-dependently (0.1 microM-30 microM) relaxed ring segments of canine femoral, mesenteric, and renal arteries which were partially precontracted with 1 micron phenylephrine or norepinephrine, but did not relax those precontracted with 5 microM prostaglandin F2 alpha or 40 mM K+. The relaxation was not significantly inhibited by pretreatment with 10 microM propranolol or metoprolol. Deno produced a parallel rightward shift in concentration-response curves to phenylephrine in femoral and renal arteries. The Schild plot yielded linear regressions of slopes of 1.301 +/- 0.106 and 0.823 +/- 0.122, respectively, which were not significantly different from unity. The pA2 values of Deno against phenylephrine in femoral and renal arteries were 5.41 +/- 0.03 and 5.76 +/- 0.06, respectively. On the other hand, Deno concentration-dependently (10 nM-10 microM) relaxed ring segments of canine coronary arteries which were partially precontracted with 5 microM prostaglandin F2 alpha. The relaxation was significantly inhibited by pretreatment with 10 microM metoprolol. In conclusion, vascular smooth muscle relaxation by Deno was mediated through beta 1-adrenergic action in canine coronary arteries and through the blocking effect of alpha-adrenoceptors in canine femoral, mesenteric, and renal arteries.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905873     DOI: 10.1007/bf01744739

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  19 in total

1.  Beta-adrenergic receptors in coronary and skeletal muscle arteries.

Authors:  G D Baron; R N Speden; D F Bohr
Journal:  Am J Physiol       Date:  1972-10

Review 2.  Regulation of large coronary arteries.

Authors:  M A Young; S F Vatner
Journal:  Circ Res       Date:  1986-12       Impact factor: 17.367

3.  Alpha-adrenergic regulation of the coronary circulation in the conscious dog.

Authors:  S F Vatner
Journal:  Am J Cardiol       Date:  1983-07-20       Impact factor: 2.778

4.  Autoradiographic localization and densitometric analysis of beta-1 and beta-2 adrenoceptors in the canine left anterior descending coronary artery.

Authors:  P Molenaar; C R Jones; L R McMartin; R J Summers
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

Review 5.  Effects of the adrenergic transmitter on epicardial coronary arteries.

Authors:  R A Cohen; J T Shepherd; P M Vanhoutte
Journal:  Fed Proc       Date:  1984-11

6.  Cardiovascular effects of the new positive inotropic agent denopamine with special reference to species difference and the effect on failing heart.

Authors:  T Ikeo; T Nagao; S Murata; H Yabana; M Sato; H Nakajima
Journal:  Arzneimittelforschung       Date:  1986-07

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts.

Authors:  M Kino; Y Hirota; S Yamamoto; K Sawada; M Moriguchi; M Kotaka; S Kubo; K Kawamura
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

9.  Cardiovascular effects and plasma levels of denopamine (TA-064), a new positive inotropic agent, in chronically instrumented dogs.

Authors:  T Ikeo; T Nagao; T Suzuki; H Yabana; H Nakajima
Journal:  Jpn J Pharmacol       Date:  1985-10

10.  Studies on the affinity and selectivity of denopamine (TA-064), a new cardiotonic agent, for beta-adrenergic receptors.

Authors:  K Naito; T Nagao; M Otsuka; S Harigaya; H Nakajima
Journal:  Jpn J Pharmacol       Date:  1985-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.